Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 3

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 9Small Cell Lung Carcinoma 6Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Neoplasms by Site 3Neoplasm Metastasis 3Endometrial Neoplasms 3Cholangiocarcinoma 3Neoplasms by Histologic Type 2Liver Neoplasms 2Gallbladder Neoplasms 2Bile Duct Neoplasms 2Vaccinia 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Resectable Intrahepatic Cholangiocarcinoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oropharyngeal Neoplasms 1Non-Small Cell Lung Cancer Metastatic 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Glandular and Epithelial 1

Interventions

Gemcitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 8Cisplatin 7pembrolizumab 6Radiation 5Mitomycin 4Fluorouracil 4Cystoscopy 4enfortumab vedotin 3durvalumab 3dehydroftorafur 3avelumab 3Transurethral Resection of Bladder 3Radiotherapy 3Platinum 3Nivolumab 3Mitozytrex 3Cystectomy 31,2-diaminocyclohexaneplatinum II citrate 3ulixertinib 2tremelimumab 2erdafitinib 2atezolizumab 2Paclitaxel 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × durvalumab × 30 days × Clear all
NCT04960709 2026-06-04

VOLGA

AstraZeneca

Phase 3 Active not recruiting
712 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03682068 2026-05-28

NILE

AstraZeneca

Phase 3 Active not recruiting
1,246 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
11 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡